Milestone Pharmaceuticals Inc. Shareholders' Equity
Milestone Pharmaceuticals Inc. (MIST) had Shareholders' Equity of $18.22 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $18.22M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $36.05M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $41.77M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $20.50M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $18.22M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $36.05M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $41.77M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $20.50M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$17.75M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$6.12M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $13.15M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $24.01M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $31.98M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $39.92M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $16.77M 10-K · filed 2026-03-20 | |
| 2023-09-30 | $28.50M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $40.41M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $53.94M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $66.35M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $77.16M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $86.66M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $100.76M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $112.60M 10-K · filed 2024-03-21 | |
| 2021-09-30 | $127.42M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $139.59M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $131.99M 10-Q · filed 2022-08-10 | |
| 2020-12-31 | $143.12M 10-K · filed 2023-03-29 | |
| 2020-09-30 | $102.20M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $88.02M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $99.63M 10-Q · filed 2021-08-11 | |
| 2019-12-31 | $114.92M 10-K · filed 2022-03-24 | |
| 2019-09-30 | $132.83M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $145.31M 10-Q · filed 2020-11-13 | |
| 2019-03-31 | $73.33M 10-Q · filed 2020-11-13 | -$65.43M 10-Q · filed 2019-06-19 |
| 2018-12-31 | $83.55M 10-K · filed 2021-03-29 | -$55.21M 10-Q · filed 2019-06-19 |
| 2017-12-31 | $25.98M 10-K/A · filed 2020-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |